Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LUCY NASDAQ:NMTC NASDAQ:POAI NASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLUCYInnovative Eyewear$1.05-2.8%$0.94$0.66▼$2.30$6.92M2.7113.34 million shs1.35 million shsNMTCNeuroOne Medical Technologies$2.66-7.6%$3.58$2.57▼$6.96$25.07M0.5446,659 shs17,600 shsPOAIPredictive Oncology$7.36+5.6%$6.70$0.71▼$16.54$24.98M1.35473,545 shs107,947 shsPSTVPlus Therapeutics$4.17+4.3%$5.17$2.90▼$23.42$27.54M1.4206,091 shs374,936 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLUCYInnovative Eyewear0.00%+42.11%+24.12%-1.82%-49.06%NMTCNeuroOne Medical Technologies0.00%-4.00%-11.11%-36.06%-32.58%POAIPredictive Oncology0.00%+3.95%+2.79%+84.92%-37.89%PSTVPlus Therapeutics0.00%+0.50%-20.16%-26.06%-55.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLUCYInnovative Eyewear$1.05-2.8%$0.94$0.66▼$2.30$6.92M2.7113.34 million shs1.35 million shsNMTCNeuroOne Medical Technologies$2.66-7.6%$3.58$2.57▼$6.96$25.07M0.5446,659 shs17,600 shsPOAIPredictive Oncology$7.36+5.6%$6.70$0.71▼$16.54$24.98M1.35473,545 shs107,947 shsPSTVPlus Therapeutics$4.17+4.3%$5.17$2.90▼$23.42$27.54M1.4206,091 shs374,936 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLUCYInnovative Eyewear0.00%+42.11%+24.12%-1.82%-49.06%NMTCNeuroOne Medical Technologies0.00%-4.00%-11.11%-36.06%-32.58%POAIPredictive Oncology0.00%+3.95%+2.79%+84.92%-37.89%PSTVPlus Therapeutics0.00%+0.50%-20.16%-26.06%-55.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLUCYInnovative Eyewear 1.50ReduceN/AN/ANMTCNeuroOne Medical Technologies 2.40Hold$11.67338.60% UpsidePOAIPredictive Oncology 1.00SellN/AN/APSTVPlus Therapeutics 2.43Hold$56.401,252.52% UpsideCurrent Analyst Ratings BreakdownLatest LUCY, PSTV, NMTC, and POAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026PSTVPlus Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $57.006/3/2026LUCYInnovative Eyewear Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/13/2026NMTCNeuroOne Medical Technologies LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.60 ➝ $8.005/11/2026NMTCNeuroOne Medical Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026LUCYInnovative Eyewear Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PSTVPlus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLUCYInnovative Eyewear$2.66M2.53N/AN/A$1.69 per share0.62NMTCNeuroOne Medical Technologies$12.10M1.91N/AN/A$0.85 per share3.13POAIPredictive Oncology$1.66M15.01N/AN/A($0.46) per share-16.00PSTVPlus Therapeutics$5.21M5.51N/AN/A$0.72 per share5.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLUCYInnovative Eyewear-$7.59M-$1.69N/AN/AN/A-272.42%-83.37%-76.02%8/13/2026 (Estimated)NMTCNeuroOne Medical Technologies-$3.61M-$0.85N/AN/AN/A-68.35%-99.43%-70.40%8/13/2026 (Estimated)POAIPredictive Oncology-$12.66M-$13.50N/AN/AN/A-5,065.23%-732.73%-235.55%N/APSTVPlus Therapeutics-$22.39M-$2.30N/AN/AN/A-230.24%-198.48%-73.13%8/13/2026 (Estimated)Latest LUCY, PSTV, NMTC, and POAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026PSTVPlus Therapeutics-$0.8480-$1.05-$0.2020-$1.05$0.97 million$1.03 million5/14/2026Q1 2026LUCYInnovative Eyewear-$0.47-$0.37+$0.10-$0.37$0.70 million$0.77 million5/12/2026Q2 2026NMTCNeuroOne Medical Technologies-$0.2267-$0.25-$0.0233-$0.28$2.58 million$1.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLUCYInnovative EyewearN/AN/AN/AN/AN/ANMTCNeuroOne Medical TechnologiesN/AN/AN/AN/AN/APOAIPredictive OncologyN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLUCYInnovative EyewearN/A8.026.09NMTCNeuroOne Medical TechnologiesN/A4.213.28POAIPredictive OncologyN/A0.010.01PSTVPlus TherapeuticsN/A2.272.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLUCYInnovative Eyewear0.96%NMTCNeuroOne Medical Technologies16.07%POAIPredictive Oncology9.04%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipLUCYInnovative Eyewear1.66%NMTCNeuroOne Medical Technologies11.80%POAIPredictive Oncology1.21%PSTVPlus Therapeutics2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLUCYInnovative Eyewear96.40 million6.30 millionNot OptionableNMTCNeuroOne Medical Technologies208.70 million7.68 millionOptionablePOAIPredictive Oncology303.39 million3.35 millionNot OptionablePSTVPlus Therapeutics206.88 million6.71 millionNot OptionableLUCY, PSTV, NMTC, and POAI HeadlinesRecent News About These CompaniesPlus Therapeutics, Inc. (NASDAQ:PSTV) Given Consensus Recommendation of "Hold" by BrokeragesJuly 9, 2026 | americanbankingnews.comPlus Therapeutics (NASDAQ:PSTV) Trading Down 3.2% - What's Next?July 8, 2026 | americanbankingnews.comPlus Therapeutics Inc.July 2, 2026 | barrons.comPlus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV)June 30, 2026 | finance.yahoo.comPlus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy TranscriptJune 30, 2026 | seekingalpha.comPlus Therapeutics to Rebrand as Cerenome, Affirm 2026 Guidance and Report CNSide Commercial ProgressJune 30, 2026 | quiverquant.comQPlus Therapeutics Provides Mid-Year Business Update Including Corporate RebrandingJune 30, 2026 | globenewswire.comPlus Therapeutics Subsidiary CNSide Diagnostics Signs National Coverage Agreement with Elevance Health for CNSide CSF Tumor Cell Enumeration AssayJune 25, 2026 | quiverquant.comQPlus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS CancerJune 25, 2026 | globenewswire.comPlus Therapeutics to Provide Business Update Call on June 30, 2026June 23, 2026 | globenewswire.comPlus Therapeutics Launches New At-The-Market Equity ProgramJune 5, 2026 | tipranks.comPlus Therapeutics gains CAP accreditation for CNSide CSF assay platformJune 4, 2026 | proactiveinvestors.comCNSide Diagnostics, a Plus Therapeutics Subsidiary, Achieves Prestigious CAP Accreditation for Clinical LaboratoryJune 4, 2026 | quiverquant.comQPlus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical LaboratoryJune 4, 2026 | globenewswire.comPlus Therapeutics Showcases CNSide's Impact on Early Diagnosis and Cost Reduction at ISPOR Annual MeetingMay 26, 2026 | quiverquant.comQPlus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal MetastasesMay 26, 2026 | globenewswire.comPlus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS OncologyMay 19, 2026 | globenewswire.comPlus Therapeutics Stockholders Back Directors and Incentive PlanMay 15, 2026 | tipranks.comPlus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2026 | zacks.comPlus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial RolloutMay 15, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLUCY, PSTV, NMTC, and POAI Company DescriptionsInnovative Eyewear NASDAQ:LUCY$1.05 -0.03 (-2.78%) Closing price 04:00 PM EasternExtended Trading$1.00 -0.05 (-4.76%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.NeuroOne Medical Technologies NASDAQ:NMTC$2.66 -0.22 (-7.64%) Closing price 04:00 PM EasternExtended Trading$2.66 0.00 (0.00%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.Predictive Oncology NASDAQ:POAI$7.36 +0.39 (+5.60%) As of 07/10/2026Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.Plus Therapeutics NASDAQ:PSTV$4.17 +0.17 (+4.25%) Closing price 04:00 PM EasternExtended Trading$4.16 -0.01 (-0.22%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The SK Hynix IPO and 2027’s AI Memory Squeeze Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Analysts See Major Upside for These 5 Stocks One Short- and One Long-Term ETF for Quantum Computing Bulls Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
